title: The effect of early versus delayed challenge after vaccination in controlling SHIV 89.6P infection.
abstract: We sought to determine how effectively a CD8+ T cell inducing vaccine controls SHIV-89.6P infection in rhesus macaques at a range of challenge times post-vaccination. To this end, twenty eight Mamu-A*01+ rhesus macaques were given replication incompetent human serotype 5 adenovirus vector expressing SIVmac239 gag DNA and boosted 24 weeks later. Groups of 4 monkeys were then challenged with SHIV-89.6P at 1, 3, 6, 12, and 24 weeks after the boost. We compared the kinetics of viral load, CD4+ and virus-specific CD8+ T cells in these macaques. Measurements of CD8+ T cells taken before challenge show an exponential decay between 1 and 12 weeks following vaccination (p<0.0001). After week 12, no further decay was observed. Twenty of 24 vaccinated animals maintained more CD4+ T cells and kept their viral load at least one order of magnitude lower than the control animals throughout the chronic phase of the study. All 24 vaccinated animals survived the duration of the study. The viral and T cell kinetics over the first two weeks differed between the vaccinated groups, with more recent vaccination improving the early control of virus (p-value=0.027). The rates of virus specific CD8+ T cell expansion were greater in animals having higher viral loads at one week (r=0.45, p=0.029), suggesting that the kinetics of early viral load may have a role in virus specific CD8+ T cell generation, although these early differences did not lead to different clinical outcomes within the vaccinated animals.
authors.affiliation: Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, Los Alamos, NM 87545, USA.
authors.forename: Leslie L
authors.initials: LL
authors.lastname: Chavez
authors.forename: Miles P
authors.initials: MP
authors.lastname: Davenport
authors.forename: John W
authors.initials: JW
authors.lastname: Shiver
authors.forename: Lynda G
authors.initials: LG
authors.lastname: Tussey
authors.forename: Kara S
authors.initials: KS
authors.lastname: Cox
authors.forename: Margaret
authors.initials: M
authors.lastname: Bachinsky
authors.forename: Fubao
authors.initials: F
authors.lastname: Wang
authors.forename: Lingyi
authors.initials: L
authors.lastname: Huang
authors.forename: William A
authors.initials: WA
authors.lastname: Schleif
authors.forename: Mary-Ellen
authors.initials: ME
authors.lastname: Davies
authors.forename: Aimin
authors.initials: A
authors.lastname: Tang
authors.forename: Danilo R
authors.initials: DR
authors.lastname: Casimiro
authors.forename: Alan S
authors.initials: AS
authors.lastname: Perelson
authors.forename: Ruy M
authors.initials: RM
authors.lastname: Ribeiro
mesh_terms: D000818:Animals; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology; D006801:Humans; D008253:Macaca mulatta / Q000276:immunology*; D018449:SAIDS Vaccines / Q000276:immunology*; D016097:Simian Acquired Immunodeficiency Syndrome / Q000276:immunology* / Q000517:prevention & control / Q000821:virology; D015302:Simian Immunodeficiency Virus / Q000235:genetics / Q000276:immunology*; D013997:Time Factors; D014611:Vaccination; D019562:Viral Load
chemical_list: D018449:SAIDS Vaccines
references.citation: J Immunol Methods. 2002 Oct 1;268(1):9-19
references.pmid: 12213338
references.citation: J Immunol. 2003 Oct 15;171(8):3928-35
references.pmid: 14530309
references.citation: Virology. 2008 May 10;374(2):322-37
references.pmid: 18252262
references.citation: Virus Genes. 2008 Feb;36(1):105-15
references.pmid: 18049888
references.citation: Arch Virol. 2008;153(3):463-72
references.pmid: 18080858
references.citation: Nat Med. 2002 Mar;8(3):207-10
references.pmid: 11875482
references.citation: J Virol. 2005 Aug;79(15):10059-62
references.pmid: 16014966
references.citation: Immunol Rev. 2007 Apr;216:164-75
references.pmid: 17367342
references.citation: J Virol. 2005 Dec;79(24):15547-55
references.pmid: 16306625
references.citation: J Virol. 2008 Apr;82(8):4149-53
references.pmid: 18234787
references.citation: J Gen Virol. 2008 Feb;89(Pt 2):540-5533
references.pmid: 18198386
references.citation: Nature. 2001 Mar 1;410(6824):106-11
references.pmid: 11242051
references.citation: Nature. 2002 Jan 17;415(6869):331-5
references.pmid: 11797011
references.citation: J Virol. 2004 Sep;78(18):10096-103
references.pmid: 15331742
references.citation: Virology. 2005 Mar 15;333(2):226-38
references.pmid: 15721357
references.citation: J Acquir Immune Defic Syndr. 2006 Mar;41(3):259-65
references.pmid: 16540926
references.citation: Viral Immunol. 2005;18(4):689-94
references.pmid: 16359235
references.citation: Eur J Immunol. 2001 Apr;31(4):1115-21
references.pmid: 11298336
references.citation: N Engl J Med. 2007 May 17;356(20):2073-81
references.pmid: 17507706
references.citation: J Virol. 2005 Jul;79(14):9228-35
references.pmid: 15994817